Pain Medicine, Interventional Pain Medicine · Lexington, KY
NPI
1164518080
Since 2006
Specialty
Pain Medicine, Interventional Pain Medicine
Code 208VP0014X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2700 Old Rosebud Rd Ste 330
Lexington, KY, 40509
Phone (859) 523-1776
Groups this clinician bills Medicare through
Medicare paid, 2024
$487K
10,045 services
Medicare patients, 2024
596
Average age 66
Drug cost, 2024
$721K
30,975 prescriptions
Company payments, 2025
$386
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David P Bosomworth II was code Q9966 (low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml), 3,200 times for 36 patients. In total David P Bosomworth II billed 10,045 services in 57 codes, and Medicare paid $487K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-09-17.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q9966 Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | Office | 3,200 | 36 | $0.29 | $915 |
| 99213 Office E&M - Established | Office | 1,957 | 562 | $54.23 | $106K |
| 80307 Drug Tests | Office | 1,952 | 541 | $59.26 | $116K |
| G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 615 | 388 | $236.41 | $145K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 604 | 18 | $0.09 | $53.62 |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 336 | 48 | $0.77 | $257 |
| 77002 Imaging - Miscellaneous | Office | 77 | 38 | $74.65 | $5,748 |
| 99214 Office E&M - Established | Office | 70 | 57 | $79.11 | $5,538 |
| G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 62 | 52 | $112.14 | $6,953 |
| 62370 Musculoskeletal | Office | 59 | 29 | $51.32 | $3,028 |
| 20610 Joint Injection | Office | 58 | 30 | $52.74 | $3,059 |
| 64635 Destruction by Neurolytic Agent - Back | Office | 58 | 44 | $423.48 | $25K |
| 64636 Destruction by Neurolytic Agent - Back | Office | 56 | 43 | $227.09 | $13K |
| 76942 Ultrasound - Nonspecific | Office | 51 | 23 | $33.27 | $1,697 |
| J1030 Injection, methylprednisolone acetate, 40 mg | Office | 39 | 29 | $5.04 | $196 |
By year: 2022 $342K for 7,262 services; 2023 $600K for 13,558 services; 2024 $487K for 10,045 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80307 Drug Tests | 1,952 | 541 | $59.26 | $116K |
| G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 615 | 388 | $236.41 | $145K |
| G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | 62 | 52 | $112.14 | $6,953 |
Medicare prescription drug claims, 2024
In 2024, the drug David P Bosomworth II prescribed most often to Medicare patients was Hydrocodone-Acetaminophen (Hydrocodone/Acetaminophen), with 7,615 prescriptions and refills. In total David P Bosomworth II wrote 30,975 Medicare prescriptions that cost $721K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | 7,615 | 7,621 | 1,081 | $140K |
| Gabapentin Generic | 7,178 | 7,283 | 1,029 | $69K |
| Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen | 4,613 | 4,613 | 637 | $92K |
| Oxycodone Hcl Generic | 2,024 | 2,026 | 257 | $32K |
| Tizanidine Hcl Generic | 1,821 | 1,934 | 341 | $19K |
| Pregabalin Generic | 1,033 | 1,051 | 183 | $29K |
| Cyclobenzaprine Hcl Generic | 951 | 977 | 218 | $6,203 |
| Methadone Hcl Generic | 650 | 650 | 76 | $12K |
| Methocarbamol Generic | 615 | 633 | 159 | $4,859 |
| Baclofen Generic | 609 | 647 | 126 | $4,670 |
| Diclofenac Sodium Generic | 472 | 480 | 137 | $13K |
| Meloxicam Generic | 463 | 512 | 109 | $1,458 |
| Ibuprofen Generic | 435 | 473 | 84 | $3,249 |
| Amitriptyline Hcl Generic | 385 | 423 | 71 | $2,009 |
| Tramadol Hcl Generic | 270 | 278 | 55 | $4,035 |
Brand drugs: 355 claims; generic drugs: 30,620 claims; opioid claims: 15,548.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David P Bosomworth II $386 ($386 in general payments such as food, travel and fees) from 8 companies. The largest payer was Saluda Medical Americas, Inc. with $142.
| Company | Payments | Amount |
|---|---|---|
| Saluda Medical Americas, Inc. | 7 | $142 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 5 | $95.35 |
| Boston Scientific Corporation BSX | 1 | $34.79 |
| Valinor Pharma, LLC | 2 | $30.34 |
| Abbvie Inc. ABBV | 1 | $28.09 |
| Vertex Pharmaceuticals Incorporated VRTX | 1 | $19.66 |
| Azurity Pharmaceuticals, Inc. | 1 | $18.31 |
| Tonix Medicines, Inc. | 1 | $16.56 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.